Region Gaevleborg

Running trials

• Recruiting

  The HIt HArd and hiT Early in Multiple Sclerosis Trial

  NCT07517185· Phase 2· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Source

• Recruiting

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· Phase 2/3· Source

• Recruiting

  Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)

  2023-506998-35-00· Phase 3· Source

• Recruiting

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  NCT06488482· Phase 3· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Source

• Recruiting

  SACK

  2022-501600-10-00· Phase 3· Source

• Active, not recruiting

  Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

  NCT05687266· Phase 3· Source

• Recruiting

  ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study

  2024-518172-31-01· Phase 3· Source

• Active, not recruiting

  Methotrexate in Patients with Early Rheumatoid Arthritis

  NCT05353829· Phase 4· Source

• Active, not recruiting

  Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with extensive stage small-cell lung cancer?

  NCT05223647· Phase 3· Source

• Recruiting

  Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

  NCT04910802· Phase 4· Source

• Active, not recruiting

  NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

  NCT04335669· Phase 3· Source

• Active, not recruiting

  Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

  NCT03540420· Phase 2· Source

• Completed

  Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

  NCT03446547· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Melanoma2 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Glioblastoma1 recruiting
• Multiple sclerosis1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Active, not recruiting

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06497556· Phase 3· Source

• Completed

  Sotorasib (AMG 510) in Subjects with NSCLC with KRASG12C Mutation in Need of First-Line Treatment

  NCT04933695· Phase 2· Source

• Active, not recruiting

  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

  NCT04655976· Phase 2/3· Source

• Completed

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· Phase 3· Source

• Completed

  SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

  NCT03982381· Phase 4· Source

• Completed

  Beta-blockers to Patients With Chronic Obstructive Pulmonary Disease

  NCT03566667· Phase 4· Source

• Completed

  Intermittent ibrutinib in chronic lymphocytic leukemia

  2023-508638-32-00· Phase 1· Source